Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic (Q46558961)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 20, 2011

Language	Label	Description	Also known as
English	Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic	scientific article published on June 20, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic (English)

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

0 references

Central African Republic

1 reference

based on heuristic

inferred from title

Charlotte Charpentier

1

object named as

Charlotte Charpentier

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

9

object named as

Laurent Bélec

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

5

object named as

Mathieu Matta

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Jean De Dieu Longo

8

object named as

Jean De Dieu Longo

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

author name string

Jean-Chrysostome Gody

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Olivia Mbitikon

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Sandrine Moussa

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Hélène Péré

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Julien Fournier

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21599597

2 December 2024

publication date

20 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

full work available at URL

http://www.liebertpub.com/doi/pdf/10.1089/aid.2011.0035

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

AIDS Research and Human Retroviruses

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

28

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

87-94

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens

1

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia

2

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland

3

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care

4

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali

5

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children

6

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa

7

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program

8

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations

9

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire

10

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire

11

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine

12

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure

13

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy

14

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

First Data on HIV-1 Resistance Mutations to Antiretroviral Drugs in Central African Republic

15

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

16

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Running with scissors: using antiretroviral therapy without monitoring viral load

17

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Management of paediatric HIV-1 resistance

18

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Monitoring of highly active antiretroviral therapy in HIV infection.

19

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test

20

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients

21

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth

22

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis

23

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy

24

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya

25

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care

26

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children

27

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure

29

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine

31

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon

32

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children

33

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns

34

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine

35

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

36

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens

37

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria

38

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms

39

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).

40

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

41

1 reference

10.1089/AID.2011.0035

https://api.crossref.org/works/10.1089/AID.2011.0035

2 December 2024

Identifiers

10.1089/AID.2011.0035

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21599597

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46558961&oldid=2282789878"